Oncology Specialists, S.C.
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Oncology Specialists, S.C. sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).
Oncology Specialists, S.C.: 10 sponsored US clinical trials, none currently recruiting.
Oncology Specialists, S.C. sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 0 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lymphoma, Non-Hodgkin, with 1 trials.
Top-decile sponsor footprint
Oncology Specialists, S.C. ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
7 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (70.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
10 total, page 1 of 1
Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas
NCT01078922
Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients
NCT00919035
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients
NCT00654186
Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)
NCT00424385
Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer
NCT00414388
VELCADE,Rituximab,Cyclophosphamide and Decadron
NCT00413959
GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere
NCT00274287
Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer
NCT00272038
Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)
NCT00156013
Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer
NCT00145418
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 7 |
Therapeutic Areas
How the Oncology Specialists, S.C. early-phase archive is shaped
10 indexed studies, none listed as recruiting (0% open); 7 completed (70%).
Phase mix: 0 late (III/IV) vs 10 early (I/II) (early-phase heavy).
Top condition: Lymphoma, Non-Hodgkin (1 trial), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Oncology Specialists, S.C.: archived-pipeline peers nationwide
Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Oncology Specialists, S.C. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 10 archived trials
- Adamas Pharmaceuticals · 10 trials · 0% recruiting
- Adverum Biotechnologies · 10 trials · 30% recruiting
- Aevi Genomic Medicine, LLC, a Cerecor company · 10 trials · 0% recruiting
- Agouron Pharmaceuticals · 10 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Oncology Specialists, S.C. page
10 registered trials is a research-attention snapshot, not an endorsement of Oncology Specialists, S.C. or any single study.
- None of Oncology Specialists, S.C.'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Lymphoma, Non-Hodgkin is the condition Oncology Specialists, S.C. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lymphoma, Non-Hodgkin trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Oncology Specialists, S.C. pipeline card: 10 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.